相关实验视频
Updated: Jan 8, 2026

05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
7.2K
SGLT2抑制剂与降低2型糖尿病患者肝细胞癌风险的关联
Jonggi Choi1,2,3, Vy H Nguyen4, Eric Przybyszewski2,3
1Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
The American journal of gastroenterology
|December 16, 2025
概括
-葡萄糖携带载体-2 抑制剂 (SGLT2is) 在2型糖尿病 (T2DM) 患者中显示降低了肝细胞癌 (HCC) 风险. 这一发现支持SGLT2is作为T2DM中HCC的潜在化学预防疗法.
科学领域:
- 内分泌学 在内分泌学.
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
背景情况:
- -葡萄糖携带载体-2 抑制剂 (SGLT2is) 是一种常见的2型糖尿病 (T2DM) 治疗方法.
- 对于SGLT2的潜在肝保护作用,需要对肝癌风险进行调查.
研究的目的:
- 评估SGLT2抑制剂使用与肝细胞癌 (HCC) 风险之间的关联.
- 为了比较T2DM患者开始SGLT2i与其他抗糖尿病药物之间的HCC风险.
主要方法:
- 使用美国和韩国医疗中心 (2013-2024) 电子健康记录进行的回顾性队列研究.
- 包括有T2DM发起SGLT2i,DPP4i,GLP-1RA或硫基尿酸的成年人.
- 使用了6个月的里程碑分析和反向概率权重与精细灰色竞争风险模型.
主要成果:
- 与硫尿素 (SHR 0.44) 和DPP4抑制剂 (SHR 0.53) 相比,SGLT2i的使用与显著降低HCC风险有关.
- 在SGLT2i和GLP-1RA使用者之间,HCC风险是可比的 (SHR 0.87).
- 保护作用在各个子组中一致,包括年轻患者,男性和慢性肝病患者.
结论:
- 在T2DM患者中,SGLT2抑制剂治疗与降低HCC风险有关.
- 研究结果表明,SGLT2抑制剂对HCC.有潜在的化学预防作用.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562
Dipeptidyl Peptidase 4 Inhibitors
557
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
557
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
505
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
505
Oral Hypoglycemic Agents: Sulfonylureas
724
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
724
Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565

